PL2830666T3 - Skuteczna synteza koniugatów etylenodicysteina-cukier do obrazowania i terapii - Google Patents
Skuteczna synteza koniugatów etylenodicysteina-cukier do obrazowania i terapiiInfo
- Publication number
- PL2830666T3 PL2830666T3 PL13767943T PL13767943T PL2830666T3 PL 2830666 T3 PL2830666 T3 PL 2830666T3 PL 13767943 T PL13767943 T PL 13767943T PL 13767943 T PL13767943 T PL 13767943T PL 2830666 T3 PL2830666 T3 PL 2830666T3
- Authority
- PL
- Poland
- Prior art keywords
- ethylenedicysteine
- therapy
- imaging
- efficient synthesis
- sugar conjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/10—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to heterocyclic rings
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261615684P | 2012-03-26 | 2012-03-26 | |
| PCT/US2013/033919 WO2013148710A1 (en) | 2012-03-26 | 2013-03-26 | Efficient synthesis of ethylenedicysteine-sugar conjugates for imaging and therapy |
| EP13767943.7A EP2830666B1 (en) | 2012-03-26 | 2013-03-26 | Efficient synthesis of ethylenedicysteine-sugar conjugates for imaging and therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2830666T3 true PL2830666T3 (pl) | 2021-03-08 |
Family
ID=49261180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13767943T PL2830666T3 (pl) | 2012-03-26 | 2013-03-26 | Skuteczna synteza koniugatów etylenodicysteina-cukier do obrazowania i terapii |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9549995B2 (pl) |
| EP (1) | EP2830666B1 (pl) |
| JP (1) | JP6336695B2 (pl) |
| KR (1) | KR102040476B1 (pl) |
| CN (1) | CN104321083B (pl) |
| AU (1) | AU2013239870B2 (pl) |
| BR (1) | BR112014023988B1 (pl) |
| CA (1) | CA2868857C (pl) |
| DK (1) | DK2830666T3 (pl) |
| ES (1) | ES2782504T3 (pl) |
| HK (1) | HK1204567A1 (pl) |
| HU (1) | HUE048557T2 (pl) |
| IL (1) | IL234858A (pl) |
| IN (1) | IN2014DN08487A (pl) |
| PL (1) | PL2830666T3 (pl) |
| PT (1) | PT2830666T (pl) |
| RS (1) | RS60085B1 (pl) |
| RU (1) | RU2674673C2 (pl) |
| SI (1) | SI2830666T1 (pl) |
| WO (1) | WO2013148710A1 (pl) |
| ZA (1) | ZA201407213B (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107955053B (zh) * | 2017-12-11 | 2019-10-29 | 江西宇能制药有限公司 | 一种左炔诺孕酮中间体乙基锂氨物的制备方法 |
| WO2023077375A1 (en) * | 2021-11-04 | 2023-05-11 | Shenzhen Xpectvision Technology Co., Ltd. | In vivo xrf agent |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4925650A (en) * | 1988-11-16 | 1990-05-15 | Mallinckrodt, Inc. | Technetium -99m complex for examining the renal function |
| US6407071B1 (en) | 1998-06-04 | 2002-06-18 | Co-Enzyme Technology Ltd. | Method and composition for treating malignant cells |
| US7067111B1 (en) * | 1999-10-25 | 2006-06-27 | Board Of Regents, University Of Texas System | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging |
| US6692724B1 (en) | 1999-10-25 | 2004-02-17 | Board Of Regents, The University Of Texas System | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging |
| EP1286704B1 (en) | 2000-06-02 | 2014-07-23 | Board of Regents, The University of Texas System | ETHYLENEDICYSTEINE (EC)-glucose analog CONJUGATES |
| BR0316046A (pt) * | 2002-11-07 | 2005-09-13 | Univ Texas | Conjugados de fármaco e etilenodicisteìna (ec), composições e métodos para imageamento de doença especìfica de tecido |
| CN101137398B (zh) * | 2005-01-05 | 2012-07-04 | 得克萨斯大学体系董事会 | 用于双重显像和放射化疗的缀合物：组合物、生产和应用 |
| EP1926487A2 (en) | 2005-07-19 | 2008-06-04 | University of Tennessee Research Foundation | Thiazolidinone amides, thiazolidine carboxylic acid amides, and serine amides, including polyamine conjugates thereof, as selective anti-cancer agents |
| US10925977B2 (en) | 2006-10-05 | 2021-02-23 | Ceil>Point, LLC | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
| US20080107198A1 (en) | 2006-11-07 | 2008-05-08 | Innovative Sonic Limited | Method and apparatus for performing multi-input multi-output transmission in a wireless communications system |
| KR20100127845A (ko) * | 2008-03-24 | 2010-12-06 | 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 | 심근 질환의 영상-유도된 치료: 조성물, 제조 및 적용 |
-
2013
- 2013-03-26 IN IN8487DEN2014 patent/IN2014DN08487A/en unknown
- 2013-03-26 HU HUE13767943A patent/HUE048557T2/hu unknown
- 2013-03-26 CN CN201380021343.XA patent/CN104321083B/zh active Active
- 2013-03-26 PL PL13767943T patent/PL2830666T3/pl unknown
- 2013-03-26 BR BR112014023988-6A patent/BR112014023988B1/pt active IP Right Grant
- 2013-03-26 PT PT137679437T patent/PT2830666T/pt unknown
- 2013-03-26 AU AU2013239870A patent/AU2013239870B2/en active Active
- 2013-03-26 CA CA2868857A patent/CA2868857C/en active Active
- 2013-03-26 US US13/850,917 patent/US9549995B2/en active Active
- 2013-03-26 KR KR1020147030004A patent/KR102040476B1/ko active IP Right Grant
- 2013-03-26 DK DK13767943.7T patent/DK2830666T3/da active
- 2013-03-26 RS RS20200382A patent/RS60085B1/sr unknown
- 2013-03-26 RU RU2014143024A patent/RU2674673C2/ru active
- 2013-03-26 SI SI201331704T patent/SI2830666T1/sl unknown
- 2013-03-26 EP EP13767943.7A patent/EP2830666B1/en active Active
- 2013-03-26 ES ES13767943T patent/ES2782504T3/es active Active
- 2013-03-26 WO PCT/US2013/033919 patent/WO2013148710A1/en active Application Filing
- 2013-03-26 JP JP2015503472A patent/JP6336695B2/ja active Active
-
2014
- 2014-09-28 IL IL234858A patent/IL234858A/en active IP Right Grant
- 2014-10-06 ZA ZA2014/07213A patent/ZA201407213B/en unknown
-
2015
- 2015-05-29 HK HK15105156.2A patent/HK1204567A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2014143024A (ru) | 2016-05-20 |
| DK2830666T3 (da) | 2020-04-06 |
| IN2014DN08487A (pl) | 2015-05-08 |
| JP2015512408A (ja) | 2015-04-27 |
| KR20140144720A (ko) | 2014-12-19 |
| RS60085B1 (sr) | 2020-05-29 |
| EP2830666A4 (en) | 2015-11-04 |
| BR112014023988B1 (pt) | 2021-02-02 |
| IL234858A (en) | 2017-03-30 |
| WO2013148710A1 (en) | 2013-10-03 |
| ZA201407213B (en) | 2017-08-30 |
| JP6336695B2 (ja) | 2018-06-06 |
| AU2013239870A1 (en) | 2014-10-23 |
| KR102040476B1 (ko) | 2019-11-06 |
| CA2868857A1 (en) | 2013-10-03 |
| HK1204567A1 (en) | 2015-11-27 |
| SI2830666T1 (sl) | 2020-07-31 |
| PT2830666T (pt) | 2020-04-02 |
| US20130343995A1 (en) | 2013-12-26 |
| CA2868857C (en) | 2020-06-02 |
| CN104321083A (zh) | 2015-01-28 |
| CN104321083B (zh) | 2017-11-10 |
| EP2830666B1 (en) | 2020-01-08 |
| RU2674673C2 (ru) | 2018-12-12 |
| HUE048557T2 (hu) | 2020-07-28 |
| AU2013239870B2 (en) | 2017-07-20 |
| ES2782504T3 (es) | 2020-09-15 |
| US9549995B2 (en) | 2017-01-24 |
| EP2830666A1 (en) | 2015-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1213488A1 (zh) | 共軛的吡咯並苯並二氮雜卓衍生物的合成與中間體 | |
| HK1202253A1 (en) | Combination treatment of cancer | |
| SG10201508495VA (en) | Combination treatment of cancer | |
| EP2606349A4 (en) | AGENTS FOR CANCER DIAGNOSIS AND CANCER THERAPY | |
| EP2838880A4 (en) | COMPOSITIONS AND METHODS FOR NON-INVASIVE IMAGING | |
| HK1214128A1 (zh) | 癌症的治療 | |
| EP2707710A4 (en) | DIAGNOSIS OF CANCER | |
| GB201003293D0 (en) | Cancer vaccine | |
| GB201217892D0 (en) | Treatment of cancer | |
| EP2911692A4 (en) | USE OF ENDOCYTOSE INHIBITORS AND ANTIBODIES FOR ANTICANCER THERAPY | |
| IL275636A (en) | Medical combination for cancer treatment | |
| HK1204956A1 (en) | Treatment of cancer | |
| SI2892925T1 (sl) | Kombinacijsko zdravljenje raka | |
| GB201218352D0 (en) | Compounds and their synthesis | |
| EP2585115A4 (en) | ANTICANCER TREATMENT | |
| ZA201407213B (en) | Efficient synthesis of ethylenedicysteine-sugar conjugates for imaging and therapy | |
| EP2548580A4 (en) | PHARMACEUTICAL FOR PSEUDOTRAINING THERAPY | |
| GB201217890D0 (en) | Treatment of cancer | |
| GB201017354D0 (en) | Treatment of cancer | |
| GB201017356D0 (en) | Combination treatment of cancer | |
| GB201020513D0 (en) | Cancer therapy | |
| IL223237A0 (en) | Diagnosis of cancer | |
| GB201222949D0 (en) | Combination Treatment of Cancer | |
| GB201222950D0 (en) | Combination treatment of cancer | |
| GB201121791D0 (en) | Combination treatment of cancer |